🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC NCT06405490Phase 21 site📍 Beijing Cancer Institute and Hospital, Chinese Academy of Medical S… · Tests: Nanoliposomal Irinotecan+Oxaliplatin +Capecitabine+Cadonilimab Advanced Therapies for Liver Metastases NCT04622423n/a1 site📍 Milan IRCCS San Raffaele Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance NCT07483983Phase 27 sites📍 Villejuif📍 Bordeaux📍 Dijon Gustave Roussy, Cancer Campus, Grand Paris · Tests: ASP3082 Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma NCT07491445Phase 382 sites📍 Phoenix📍 Scottsdale📍 Los Angeles Revolution Medicines, Inc. · Tests: daraxonrasib, gemcitabine, nab-paclitaxel BBO-11818 in Adult Subjects With KRAS Mutant Cancer NCT06917079Phase 117 sites📍 Los Angeles📍 Sacramento📍 San Diego TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · Tests: BBO-11818, Pembrolizumab, Platinum chemotherapy (cisplatin or carboplatin), Pemetrexed, Cetuximab Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma NCT07259317Phase 220 sites📍 Scottsdale📍 Los Angeles📍 Orange Corcept Therapeutics · Tests: Relacorilant, Nab-paclitaxel, Gemcitabine A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC) NCT05472259Phase 213 sites📍 Antwerp📍 Brussels📍 Brussels Belgian Group of Digestive Oncology · Tests: Nanoliposomal irinotecan, 5 FU, Leucovorin, Oxaliplatin Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors NCT04900818Phase 121 sites📍 Orange📍 Aurora📍 Layfayette I-Mab Biopharma US Limited · Tests: TJ033721 (givastomig), TJ033721 (givastomig) , nivolumab, chemotherapy, TJ033721 (givastomig), chemotherapy, TJ033721 (… Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer NCT05218889Phase 1, Phase 21 site📍 Beijing Chinese PLA General Hospital · Tests: surufatinib + camrelizumab + nab-paclitaxel + S-1, nab-paclitaxel + gemcitabine Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors NCT06040541Phase 117 sites📍 Sacramento📍 New Haven📍 Sarasota Revolution Medicines, Inc. · Tests: RMC-9805, RMC-6236 A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations NCT06835569Phase 114 sites📍 Orlando📍 Tampa📍 Boston Alterome Therapeutics, Inc. · Tests: ALTA3263, cetuximab, mFOLFOX6, Pembrolizumab, Pemetrexed + Cisplatin /Carboplatin Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors NCT06218914Phase 118 sites📍 Duarte📍 Los Angeles📍 Newport Beach AstraZeneca · Tests: NT-112: Autologous, engineered T Cells targeting KRAS G12D, AZD0240: Autologous, engineered T Cells targeting KRAS G12D AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors NCT07454642Phase 17 sites📍 Scottsdale📍 Sarasota📍 Chicago Avacta Life Sciences Ltd · Tests: AVA6103 A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer NCT07049055Phase 1, Phase 24 sites📍 El Segundo📍 Summit📍 New York Engeneic Pty Limited · Tests: E-EDV-D682, EDV-GC, Gemcitabine, Nab paclitaxel. Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors NCT07630961Phase 12 sites📍 Odense C📍 Chuo Ku Novartis Pharmaceuticals · Tests: 68Ga-DFC413, 68Ga-NNS309 A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation NCT07458347Phase 19 sites📍 Los Angeles📍 Sarasota📍 Tampa Kestrel Therapeutics, Inc. · Tests: KST-6051, Gemcitabine/nab-paclitaxel, Cetuximab, Pembrolizumab, mFOLFOX6 Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With Metastatic or Locally Advanced PDAC NCT07145450Phase 1, Phase 210 sites📍 Copenhagen📍 Berlin📍 Dresden Anocca AB · Tests: ANOC-001 (TCR-T cells targeting KRAS G12V mutation presented by specific HLA alleles), ANOC-002 (TCR-T cells targeting … Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer NCT03977233Phase 21 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: Oxaliplatin, Leucovorin, Irinotecan Hydrochloride, 5-FU A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors NCT07094204Phase 122 sites📍 Santa Monica📍 Atlanta📍 Jefferson Astellas Pharma Inc · Tests: ASP5834, panitumumab A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation NCT06179160Phase 134 sites📍 Phoenix📍 Palo Alto📍 Santa Monica Incyte Corporation · Tests: INCB161734, Cetuximab, Retifanlimab, GEMNabP, mFOLFIRINOX A Study of CEND-1 With Chemotherapy as First-Line Therapy in Patients With Pancreatic Ductal Adenocarcinoma NCT06261359Phase 21 site📍 Beijing Qilu Pharmaceutical Co., Ltd. · Tests: CEND-1, Gemcitabine, Nab paclitaxel AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors NCT07094113Phase 139 sites📍 Duarte📍 Los Angeles📍 Atlanta Amgen · Tests: AMG 410, Pembrolizumab, Panitumumab Hellenic Evaluation of the Long-Term Safety and Efficacy of NalIriFOx as a 1st-line Therapy in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) NCT07723261n/a9 sites📍 Athens📍 Athens📍 Athens Hellenic Cooperative Oncology Group Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients NCT06922591Phase 1, Phase 218 sites📍 Scottsdale📍 Denver📍 Washington D.C. Tango Therapeutics, Inc. · Tests: TNG462, RMC-9805, RMC-6236, mFOLFIRINOX, gemcitabine/nab-paclitaxel Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy NCT06937177Phase 226 sites📍 Tucson📍 Los Angeles📍 Santa Monica Endevica Bio · Tests: TCMCB07, Placebo KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer NCT06411691Phase 11 site📍 Baltimore Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Tests: KRAS Vaccine with Poly-ICLC adjuvant, Balstilimab, Botensilimab Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS NCT05379985Phase 1, Phase 221 sites📍 Orange📍 Santa Monica📍 Tampa Revolution Medicines, Inc. · Tests: RMC-6236 Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 ) NCT07621718Phase 319 sites📍 Phoenix📍 Tucson📍 New Haven Revolution Medicines, Inc. · Tests: Zoldonrasib, Placebo, Oxaliplatin, Leucovorin (Calcium Folinate), 5-Fluorouracil The KN510713 Study in Combination With mFOLFIRINOX NCT07114861Phase 1, Phase 21 site📍 Goyang-si New Cancer Cure-Bio Co.,Ltd. · Tests: Study drug: KN510 120mg/day + KN713 90mg/day, Combination Chemotherapy: mFOLFIRINOX, Study drug: KN510 120mg/day + KN71… Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma NCT07805954Phase 35 sites📍 Phoenix📍 Scottsdale📍 Jacksonville Revolution Medicines, Inc. · Tests: daraxonrasib, gemcitabine, nab-paclitaxel, zoldonrasib
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy